Novartis AG (NVS)
Healthcare • Drug Manufacturers - General
StockNYSESwitzerlandUS66987V1098
160.51 USD
+0.16% today Updated 13 Nov 2026 15:44
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Novartis AG, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:44. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
03 Feb 2027
in 82 days · 08:00 · estimate 2.23
Last results
2.46 vs 2.24 estimated
27 Oct 2026 · Beat +9.7%
Beat the estimate
9 of 12
2 missed · 1 in line · 2 beats in a row
Average surprise
+4.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 03 Feb 2027 08:00 | 2.23 | — | — | Upcoming |
| 27 Oct 2026 06:00 | 2.24 | 2.46 | +9.7% | Beat |
| 20 Jul 2026 20:00 | 2.15 | 2.41 | +12.2% | Beat |
| 27 Apr 2026 22:00 | 1.65 | 1.65 | +0.0% | In line |
| 04 Feb 2026 01:00 | 2.00 | 2.03 | +1.3% | Beat |
| 28 Oct 2025 02:00 | 2.31 | 2.25 | -2.6% | Miss |
| 17 Jul 2025 01:00 | 2.37 | 2.42 | +2.0% | Beat |
| 29 Apr 2025 01:00 | 2.17 | 2.28 | +5.0% | Beat |
| 30 Jan 2025 20:00 | 1.76 | 1.98 | +12.7% | Beat |
| 28 Oct 2024 22:00 | 1.93 | 2.06 | +6.6% | Beat |
| 17 Jul 2024 22:00 | 1.86 | 1.97 | +5.9% | Beat |
| 22 Apr 2024 22:00 | 1.68 | 1.80 | +6.9% | Beat |
| 30 Jan 2024 20:00 | 1.66 | 1.53 | -7.7% | Miss |
| 24 Oct 2023 01:00 | 1.74 | 1.74 | -0.2% | In line |
| 17 Jul 2023 21:00 | 1.76 | 1.83 | +4.0% | Beat |
| 25 Apr 2023 01:00 | 1.53 | 1.71 | +11.9% | Beat |
| 31 Jan 2023 20:00 | 1.43 | 1.52 | +6.0% | Beat |
| 25 Oct 2022 01:00 | 1.62 | 1.58 | -2.3% | Miss |
| 19 Jul 2022 01:00 | 1.54 | 1.56 | +1.4% | Beat |
| 26 Apr 2022 01:00 | 1.51 | 1.46 | -3.2% | Miss |
| 02 Feb 2022 01:00 | 1.41 | 1.40 | -1.0% | In line |
| 26 Oct 2021 03:00 | 1.66 | 1.71 | +3.2% | Beat |
| 21 Jul 2021 01:00 | 1.49 | 1.66 | +11.7% | Beat |
| 27 Apr 2021 01:00 | 1.62 | 1.52 | -6.2% | Miss |
| 25 Jan 2021 20:00 | 1.39 | 1.34 | -3.8% | Miss |
| 27 Oct 2020 02:00 | 1.45 | 1.52 | +4.9% | Beat |
| 21 Jul 2020 01:00 | 1.33 | 1.36 | +2.1% | Beat |
| 28 Apr 2020 02:00 | 1.36 | 1.56 | +15.0% | Beat |
| 28 Jan 2020 20:00 | 1.31 | 1.32 | +1.0% | Beat |
| 22 Oct 2019 01:00 | 1.35 | 1.41 | +4.6% | Beat |
| 18 Jul 2019 01:00 | 1.23 | 1.34 | +8.5% | Beat |
| 24 Apr 2019 13:00 | 1.21 | 1.21 | -0.2% | In line |
| 30 Jan 2019 01:00 | 1.30 | 1.25 | -3.5% | Miss |
| 18 Oct 2018 01:00 | 1.34 | 1.32 | -1.8% | Miss |
| 18 Jul 2018 01:00 | 1.28 | 1.29 | +1.1% | Beat |
| 19 Apr 2018 02:00 | 1.27 | 1.28 | +0.8% | In line |
| 24 Jan 2018 01:00 | 1.17 | 1.21 | +3.8% | Beat |
| 24 Oct 2017 01:00 | 1.24 | 1.29 | +3.8% | Beat |
| 18 Jul 2017 01:00 | 1.17 | 1.22 | +4.6% | Beat |
| 25 Apr 2017 01:00 | 1.10 | 1.13 | +2.3% | Beat |
| 25 Jan 2017 01:00 | 1.10 | 1.12 | +1.4% | Beat |
| 25 Oct 2016 01:00 | 1.19 | 1.23 | +3.3% | Beat |
| 19 Jul 2016 01:00 | 1.17 | 1.23 | +5.2% | Beat |
| 21 Apr 2016 02:00 | 1.16 | 1.17 | +1.2% | Beat |
| 27 Jan 2016 01:00 | 1.18 | 1.12 | -5.5% | Miss |
| 27 Oct 2015 02:00 | 1.32 | 1.27 | -3.5% | Miss |
| 21 Jul 2015 01:00 | 1.24 | 1.25 | +0.8% | In line |
| 23 Apr 2015 01:00 | 1.09 | 1.29 | +18.9% | Beat |
| 27 Jan 2015 01:00 | 1.18 | 1.21 | +2.3% | Beat |
| 28 Oct 2014 03:00 | 1.30 | 1.37 | +5.7% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 56.7B | +9.6% | 14B | 24.7% | 7.15 | +21.8% | 15.2B |
| 2024 | 51.7B | +10.8% | 11.9B | 23.1% | 5.87 | -17.3% | 13.8B |
| 2023 | 46.7B | +7.4% | 14.9B | 31.8% | 7.10 | +124.0% | 11.7B |
| 2022 | 43.5B | — | 7B | 16.0% | 3.17 | — | 12B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 163.73 | 164.18 | 159.20 | 160.51 | -1.26% | 9,021,922 | |
| 02 Nov 2026 – 06 Nov 2026 | 160.54 | 165.96 | 158.93 | 162.55 | +1.09% | 9,070,000 | |
| 26 Oct 2026 – 30 Oct 2026 | 153.53 | 164.06 | 152.02 | 160.79 | +6.40% | 13,885,700 | |
| 19 Oct 2026 – 23 Oct 2026 | 150.22 | 157.10 | 149.17 | 151.12 | +0.33% | 10,682,800 | |
| 12 Oct 2026 – 16 Oct 2026 | 143.84 | 151.83 | 142.31 | 150.62 | +4.78% | 8,457,500 | |
| 05 Oct 2026 – 09 Oct 2026 | 141.02 | 144.28 | 139.31 | 143.75 | +1.95% | 8,189,000 | |
| 28 Sep 2026 – 02 Oct 2026 | 145.77 | 147.03 | 139.95 | 141.00 | -3.07% | 10,912,500 | |
| 21 Sep 2026 – 25 Sep 2026 | 141.96 | 145.51 | 140.00 | 145.46 | +3.63% | 8,669,600 | |
| 14 Sep 2026 – 18 Sep 2026 | 141.64 | 141.64 | 137.37 | 140.37 | +2.34% | 10,697,500 | |
| 08 Sep 2026 – 11 Sep 2026 | 139.94 | 140.46 | 137.00 | 137.16 | -14.27% | 17,983,400 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice (opens in a new tab) Zacks · 12 Nov 2026 16:00
- Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data (opens in a new tab) Investor's Business Daily · 11 Nov 2026 21:02
- Is Novartis (SWX:NOVN) A Bargain Or Fully Priced Now? (opens in a new tab) Simply Wall St. · 11 Nov 2026 20:12
- Advanced Therapy Medicinal Products - Global Strategic Business Report: Capitalize on 11.8% CAGR to Secure $25.4B by 2030 as Novartis, Gilead, Bristol-Myers Squibb and Roche Compete (opens in a new tab) 11 Nov 2026 14:27
- Novartis (SWX:NOVN) Halts Pelacarsen After Trial Miss As Ianalumab Data Impresses (opens in a new tab) Simply Wall St. · 11 Nov 2026 14:15
- How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis (opens in a new tab) Investor's Business Daily · 10 Nov 2026 22:12
- Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity (opens in a new tab) 10 Nov 2026 17:30
- Former Novartis CEO on What AI Can’t Replace in the Workplace (opens in a new tab) 10 Nov 2026 17:10
- Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN (opens in a new tab) 10 Nov 2026 14:19
- Novartis ranks first place in 2026 Access to Medicine Index (opens in a new tab) 10 Nov 2026 13:00
- Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer (opens in a new tab) Zacks · 10 Nov 2026 05:50
- 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 (opens in a new tab) Zacks · 09 Nov 2026 12:43
- Market Chatter: Novartis to Discontinue Development for Cardiovascular Disease Drug (opens in a new tab) MT Newswires · 09 Nov 2026 09:45
- Novartis shelves potential blockbuster pelacarsen as landmark study fails (opens in a new tab) Investing.com · 07 Nov 2026 15:46
- Update: Market Chatter: Novartis Reports Two Confirmed Tumor Cases Linked to Neuromuscular Gene Therapy (opens in a new tab) MT Newswires · 06 Nov 2026 10:48
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 160.25 USD
- Market cap
- 303.1B
- Dividend yield
- 2.95%
- 5-year average yield
- 3.46%
- Payout ratio
- 90%
- Last dividend
- 4.7730 USD · 11 Mar 2026
- Exchange
- NYSE
- Country
- Switzerland
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 11 Mar 2026 | 4.7730 USD |
| 12 Mar 2025 | 3.9940 USD |
| 07 Mar 2024 | 3.7400 USD |
| 09 Mar 2023 | 3.4690 USD |
| 8 older dividends: create a free account to see them | |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 12.3 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 19.0 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 7.7 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 10.4 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 6.4 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 1.3 / 5 |
|
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 30.6× | Weak | 30.56× |
| P/E (forward) | 16.07× | Fair | 14.16× |
| Price / book | 8.13× | Weak | 3.5× |
| Price / sales | 5.28× | Weak | 3.33× |
| EV / EBITDA | 14.23× | Fair | 11.19× |
| Free cash flow yield | 3.7% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 75.2% | Good | 54.9% |
| Operating margin | 34% | Good | 5.8% |
| Net margin | 17.5% | Good | 1.2% |
| Return on equity | 24.3% | Good | 4.4% |
| Return on assets | 10.9% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 9.3% | Good | 10.1% |
| EPS growth / year | 31.1% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.29× | Fair | 0.4× |
| Net debt / EBITDA | 1.64× | Fair | 1.46× |
| Interest cover | 15.42× | Good | 2.17× |
| Current ratio | 0.88× | Weak | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 90.5% | Weak | 0% |
| Payout of free cash flow | 69.4% | Fair | 28.7% |
| Payout of free cash flow (3 years) | 55.7% | Fair | — |
| Dividend growth / year | 5.8% | Good | 6.5% |
| Years of rising dividends | 3 | Fair | 1.5 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow NVS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.